Clinical Trial Update: The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the safety and tolerability of XS411CN injection for primary Parkinson's disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• XS411CN injection (XS411CN)

Snippet

Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Conditions: Parkinson's Disease | Phase 1 | Status: RECRUITING